학술논문
Antiretroviral-naive and -treated HIV-1 patients can harbour more resistant viruses in CSF than in plasma
Document Type
article
Author
Soulie, C; Descamps, D; Grude, M; Schneider, V; Trabaud, M-A; Morand-Joubert, L; Delaugerre, C; Montes, B; Barin, F; Ferre, V; Raymond, S; Jeulin, H; Alloui, C; Yerly, S; Pallier, C; Reigadas, S; Signori-Schmuck, A; Guigon, A; Fafi-Kremer, S; Haim-Boukobza, S; Mirand, A; Maillard, A; Vallet, S; Roussel, C; Assoumou, L; Calvez, V; Flandre, P; Marcelin, A-G; Lagier, E; Le Guillou, H; Bettinger, D; Fleury, H; Bellecave, P; Recordon-Pinson, P; Payan, C; Vabret, A; Henquell, C; Bouvier-Alias, M; de Rougemont, A; Dos Santos, G; Morand, P; Bocket, L; Rogez, S; Andre, P; Tardy, JC; Trabaud, MA; Tamalet, C; Delamare, C; Schvoerer, E; Andre-Garnier, E; Cottalorda, J; Guinard, J; Guiguon, A; Brun-Vezinet, F; Charpentier, C; Visseaux, B; Peytavin, G; Krivine, A; Si-Mohamed, A; Avettand-Fenoel, V; Marcelin, AG; Lambert-Niclot, S; Wirden, M; Chaix, ML; Amiel, C; Giraudeau, G; Brodard, V; Plantier, JC; Chaplain, C; Bourlet, T; Stoll-Keller, F; Schmitt, MP; Barth, H; Poggi, C; Izopet, J; Chaillon, A; Marque-Juillet, S; Roque-Afonso, AM
Source
Journal of Antimicrobial Chemotherapy. 70(2)
Subject
Language
Abstract
OBJECTIVES: The neurological disorders in HIV-1-infected patients remain prevalent. The HIV-1 resistance in plasma and CSF was compared in patients with neurological disorders in a multicentre study. METHODS: Blood and CSF samples were collected at time of neurological disorders for 244 patients. The viral loads were >50 copies/mL in both compartments and bulk genotypic tests were realized. RESULTS: On 244 patients, 89 and 155 were antiretroviral (ARV) naive and ARV treated, respectively. In ARV-naive patients, detection of mutations in CSF and not in plasma were reported for the reverse transcriptase (RT) gene in 2/89 patients (2.2%) and for the protease gene in 1/89 patients (1.1%). In ARV-treated patients, 19/152 (12.5%) patients had HIV-1 mutations only in the CSF for the RT gene and 30/151 (19.8%) for the protease gene. Two mutations appeared statistically more prevalent in the CSF than in plasma: M41L (P=0.0455) and T215Y (P=0.0455). CONCLUSIONS: In most cases, resistance mutations were present and similar in both studied compartments. However, in 3.4% of ARV-naive and 8.8% of ARV-treated patients, the virus was more resistant in CSF than in plasma. These results support the need for genotypic resistance testing when lumbar puncture is performed.